Biocracked
Approach 4, conceptual metaphor, with palette D, bold color field.

A single cross-section of a rusted, mineral-crusted copper pipe stands upright at center, shot from a slightly low three-quarter angle with a shallow depth of field. Its inner wall is thickly lined with chalky white-orange scale that narrows the bore to a small opening. One side of the buildup is hard and crystalline, while the other side is softer and still forming. A thin, clean ribbon of electric green liquid (#00e676) runs through the remaining channel, a subtle accent. The backdrop is a seamless saturated mustard-yellow field. Hard, directional studio light from upper left casts a crisp, short shadow to the right. Textures are tactile and macro-sharp, with visible grit and flaking. The mood is calm, analytical and slightly cautionary.
Supplements

Bitamin K2 (MK‑7) da Ya Rage Taruwar Calcium a Jijiyoyin Zuciya Bayan Shekaru 2

Nova Chen · · 6 min read

Bitamin K2 (MK‑7) da Ya Rage Taruwar Calcium a Jijiyoyin Zuciya Bayan Shekaru 2

Wani ƙananan magani da ake sayarwa a kasuwa ya yi wani abu a wani gwajin ƙwafi‑ƙwafi da mafi yawan ƙwayoyin gina jiki ba su iya cimmawa: ya rage auna ƙaruwa da calcium a jijiyoyin zuciya na mutanen da ke da cutar zuciya tun da da. Abu ɗaya da ke da ƙalubale, kuma akwai, shi ne babu wanda ya tabbatar har yanzu ko wannan yana hana faɗuwar zuciya ɗaya.

Maganin bitamin K2 a matsayin menaquinone‑7 (MK‑7) ne. Gwajin ya kasance VitaK‑CAC, wanda aka buga a JAMA Cardiology a shekarar 2026.

Lambar Muƙamuɗi

Masu shiga gwajin suna da cutar jijiyoyin zuciya mai alamun ciwo (CAD) tare da ƙimar calcium a jijiyoyin zuciya (CAC) tsakanin 50 zuwa 400 Agatston units (AU). Sun sha 360 µg na MK‑7 a kowace rana ko placebo daidai da gwargwado tsawon shekaru biyu. Matsakaicin ƙimar CAC a kowanne rukuni ya canza kamar haka:

Rukuni Farko Shekara 1 Shekara 2
Placebo 145 AU 173 AU 214 AU
MK‑7 (360 µg/ran) 135 AU 150 AU 184 AU

Wannan na nufin haɓakar da ta kai kimanin 49 AU a rukuni na MK‑7, yayin da a rukuni placebo ta kai 69 AU. Bambanci tsakanin rukuni‑rukuni ya kasance na ƙididdiga (P = .02), har ma bayan da aka daidaita da sauran ƙimomi. Maƙasudin calcium da aka auna ta hanyar CT ya nuna irin wannan sakamako.

Calcification ya ci gaba da faruwa a rukuni na MK‑7, amma a hankali.

Waɗanda Aka Bincika

Masana sun ba da ƙwayoyin 180 ga mutane, 90 a kowanne rukuni, a asibitin jami’a guda ɗaya da asibitin ƙauye a ƙasar Netherlands. An tantance bayanai daga marasa lafiya 85 a rukuni na MK‑7 da 82 a rukuni na placebo.

  • Shekaru: matsakaicin shekara 59 (MK‑7) da 61 (placebo)
  • Jinsi: kashi 42% mata a dukkan rukuni
  • Yanayi: CAD mai alamun ciwo tare da calcium matsakaici (CAC 50‑400 AU)
  • Daidaiton asali: rukuni biyu suna kusan daidai

Wannan rukuni ne matasa‑tsakanin shekaru, tare da calcium da aka tabbatar amma ba mai tsanani ba. Sakamakon zai iya bambanta ga mutanen da ke da CAC mai tsanani, marasa alamar ciwo, ko masu fama da cutar ƙoda.

Ba Sai An Duba CAC Kaɗai Ba: Cikakken Bayani Akan Plaque

Abu mafi ban sha’awa a cikin takardar shine inda tasirin ya fito. Masu gwajin sun kuma yi CT angiography, wanda ke ba da damar ganin nau’in plaque. Haɓakar CAC ta yi daidai da yawan plaques marasa calcium da suka fara samun wani sashi na calcium a lokacin gwajin (R² = 0.17; P = .04).

Masu rubutun sun yi bayanin cewa MK‑7 na iya rage kalkulashan a plaques marasa calcium. Dangantakar R² = 0.17 ba ta da karfi sosai, don haka akwai sauran abubuwa da suka fi tasiri. Wannan na nuni da wata yiwuwar hanya, ba da tabbacin cikakken mechanisme ba.

Akwai kuma wani gwaji na ilimin halittu. Matakin MK‑7 a jini ya tashi daga matsakaicin 0.50 µg/L zuwa 6.56 µg/L a rukuni na magani (P < .001), wanda ke nuna cewa masu shiga gwajin sun sha maganin kuma jikin su ya shaƙa shi. Wannan yana da muhimmanci domin matsalar rashin ɗaukar magani na iya shafar sakamakon gwaje‑gwaje.

Tsaro

Masu binciken sun bayar da babu wata mummunar illa da ta tasiri. Don gwajin shekaru biyu na ƙwayar gina jiki, wannan alama ce mai gamsarwa, ko da yake gwajin ba zai iya gano matsaloli masu zamewa ba.

Abubuwan Da Ba Mu Sani Ba

Wannan shi ne inda ake buƙatar iyakancewa a kan labarin.

  • Mahimmancin likita ba a tabbatar ba. Masu rubutun sun ce “mahimmancin wannan sakamako a bangaren ƙarfafa plaque har yanzu ba a tantance ba.” Rage kalkulashan alama ce ta hoton hoto, ba rage bugun zuciya, bugun jini, ko mutuwa ba. Calcium ma alama ce mai rikitarwa – wasu plaques masu calcium na iya zama ƙarfi fiye da waɗanda ba su da calcium, don haka rage kalkulashan ba yana nufin alheri ba.
  • Bambancin da aka samu ƙanana ne. Kimanin 20 AU kawai ne ya raba ƙaruwa a rukuni biyu a tsawon shekaru biyu.
  • Gwajin ba shi da girma sosai. Mutane 167 da aka tantance ya isa don gano bambancin CAC, amma ba zai iya gano bambancin abubuwan kiwon lafiya ba.
  • Lokacin gwajin ya yi tsawo da ɗan tsangwama. An tattara bayanai daga 2012 zuwa 2022 “tare da wasu ɗan tsangwama.”
  • Akwai alaƙa da masana’anta. Prof. Leon Schurgers ya bayyana cewa ya karɓi tallafi daga Gnosis by Lesaffre (masana'antar MK‑7) da kuma hannun jari a Coagulation Profile, duk da cewa ba su shiga cikin aikin da aka gabatar ba. Wannan ba ya kawar da sakamakon, amma yana da mahimmanci a sani. Wani sharhi a cikin bugun mujallar ya ƙara yin nazari kan wannan sakamako.

Abubuwan Da Za A Iya Yi Da Su

Kima: Gwajin ya yi amfani da 360 µg na MK‑7 a kowace rana. Wannan shine kawai ƙimar da ke da hujja daga wannan bincike, kuma ya fi yawa fiye da yadda ake samu a yawancin multivitamins.

Nau’in: MK‑7, ba MK‑4. An gwada menaquinone‑7 kawai. Ba a gwada MK‑4 ko bitamin K1 ba, don haka ba za a iya ɗauka cewa waɗannan suna da irin tasirin ba. Hakanan an gwada MK‑7 da placebo kadai, ba a haɗe shi da wasu ƙwayoyi ba.

Lokaci: Babu cikakken bayani a takardar kan lokacin da aka ɗauki maganin. Bitamin K ya fi narkewa a abinci mai ɗan mai, don haka a ci da abinci da ke ɗauke da mai zai fi dacewa. Wannan ba gwajin da aka yi ba ne, amma shawara ce mai ma’ana.

Waɗanda zai iya amfana: Sakamakon ya shafi mutane kamar waɗanda aka zaɓa – manya‑tsakiyar shekaru da ke da CAD mai alamun ciwo da calcium matsakaici. Idan kai ko wani da ka sani yana cikin wannan yanayin, yana da kyau a tattauna da likitan zuciya. Ba zai maye gurbin statins, kulawar hawan jini, ko sauran magungunan da aka tabbatar ba.

Waɗanda ya kamata su guje shi ko su tambaya da farko:

  • Kowa da ke shan warfarin ko wani maganin hana coagulation da ke kan vitamin K. Bitamin K na iya shafar yadda waɗannan magunguna ke aiki, kuma zai iya canza INR. Kada ka fara amfani da MK‑7 ba tare da izinin likita ba.
  • Masu shan wasu anticoagulants ko masu tarihin clotting, su tuntuɓi likita kafin su sha.
  • Wanda ke tunanin zai “mayar da” calcium. Gwajin ya nuna rage ƙaruwa, ba maimaita ba.
  • Waɗanda ba su da cutar zuciya. Wannan gwaji ba ya ba da shaidar amfanin MK‑7 ga mutanen da ba su da CAD.

Ƙarshe

VitaK‑CAC gwaji ne da aka tsara da kyau, tare da placebo, kuma ya nuna rashin ƙaruwa a kalkulashan jijiyoyin zuciya da ke da sahihanci a ƙididdiga da kuma daɗin lafiya mai kyau. Wannan yana da ƙarfafa guiwa ga masu bincike, musamman da alamar da aka samu a plaques marasa calcium. Amma sakamakon yana daga alamar auna hoton ne, daga gwaji ƙanana, tare da wani bayani na rikicin sha’awa da ya kamata a lura da shi. Sai gwaje‑gwaje mafi girma su nuna rage yawan abubuwan da suka faru a zuciya, kafin a ɗauke MK‑7 a matsayin magani mai ƙarfi; a halin yanzu, yana iya zama ƙari mai amfani da za a tattauna da likitan ka.

Manazo: Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone‑7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology. 2026;11(8):719‑726. doi:10.1001/jamacardio.2026.1279. ClinicalTrials.gov: NCT01002157. PubMed.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

NC

Written by

Nova Chen

Nova Chen writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: D, bold color field.

A single cracked ceramic-white bone-shaped column, like a femur section, stands upright at the center of a saturated mustard-yellow seamless backdrop. A thin, clean hairline fracture runs through its middle. Beside it, a small golden-amber glass dropper bottle sits tipped, with one droplet suspended just above the bone and not touching it, which suggests extra vitamin D that makes no difference. The camera is at a low three-quarter angle with a shallow depth of field. Hard, directional studio light from the upper left casts a crisp, long shadow across the yellow floor. The porous bone texture is visible in fine detail. A tiny electric green (#00e676) droplet reflection glints on the glass. The mood is skeptical, cool-headed and editorial.
longevity

Vitamin D da Ake Shan Yawa don Ƙashi? Gwajin Shekaru 5 Ya Ce A'a

BY DR. SYNAPSE ·

Shin kana shan ƙarin vitamin D don ƙarfafa ƙasusuwa? Gwajin bazuwar da aka gudanar tsawon shekaru biyar a kan manyan Finnawa 2,495 ya nuna cewa ba ɗayan rukunin 1,600 IU/ran ko 3,200 IU/ran ba su rage haɗarin raunin ƙashi idan aka kwatanta da placebo. Abin mamaki, rukunin 1,600 IU ya fi samun rauni (HR 1.52), yayin da rukunin 3,200 IU ba shi da irin wannan tasiri, abin da ke nuni da yiwuwar sakamakon kuskure ne kawai. Masu halarta sun riga suna da matakin vitamin D na isasshe a farawa, don haka sakamakon ba ya shafar mutanen da ke da ƙarancin vitamin D. Ga abin da binciken ya gano, iyakokinsa, da abin da za a yi kafin yanke hukunci.

Approach: conceptual metaphor. Palette: bold color field (D).

Subject: a clear glass tube-shaped pipe, cut in cross-section, sitting on a saturated mustard-yellow backdrop. Its inner wall is lined with chalky, white mineral crust that narrows the opening on one end and thins out toward the other, showing progression slowing. A single thin electric green thread runs through the clear center as a small accent.

Camera: low three-quarter angle, shallow depth of field, macro lens, with the narrowed end sharp in the foreground and the clear end softly blurred behind.

Lighting: bright, soft studio light from the upper left with crisp highlights on the glass and a clean, warm-grey shadow cast on the yellow surface. No blue cast.

Mood: calm, precise, cautiously optimistic. The mineral texture should look real, gritty and crystalline, not cartoonish. No text or labels.
supplements

720 mcg Vitamin K2 + D3 Ya Rage Kwatancen Hanyoyin Jini ~21 % a Gwajin RCT

BY DR. SYNAPSE ·

Binciken shekaru biyu, gwaji double‑blind da aka yi a kan mutane 400 masu matuƙar calcium a jijiyoyin coronary, ya nuna cewa haɗin babban ƙima na vitamin K2 da D3 yana rage ci gaban kwatancen hanyoyin jini da kusan 21 % idan aka kwatanta da placebo (196 AU vs 248 AU). Hoto na plaque bai nuna ƙaruwa a plaque marar calcium ba, alamar da ke ba da kwanciyar hankali. Kodayake maganin ya rage ci gaba, ba ya dawo da calcium da aka riga aka tara, kuma binciken bai auna yawan bugun zuciya ko mutuwar masu shiga ba. Mahalarta sun kasance manya (tsaka‑tsakin shekaru 71) da suka riga suka samu cutar coronary mai tsanani, don haka sakamakon na iya rashin dacewa ga wasu ƙungiyoyin mutane.

Macro photograph at a low 30-degree angle of two tiny mounds on a glossy, saturated teal acrylic surface. The left mound is orange-yellow CoQ10 crystalline powder with visible faceted flakes. The right mound is dull metallic grey selenium granules. A hairline crack runs across the acrylic between them, hinting at the catch. Hard, clean studio light from the upper left throws crisp, short shadows and sparkles on the crystal edges. The background falls softly out of focus, with a thin electric green reflection streaking across the glossy surface. The palette is bold color field: teal against orange, with silver-grey accents. The mood is precise, curious and cautionary, like a lab specimen photographed for a magazine. Photorealistic, shallow depth of field, no text.
longevity

Me Zai Sake Faruwa Idan Kayan Ƙari Biyu Masu Araha Suka Rage Hadarin Mutuwar Zuciya da Rabi?

BY NOVA CHEN ·

Kayan ƙari biyu—CoQ10 da selenium—sun rage adadin mutuwar zuciya daga kashi 12.6% zuwa 5.9% a cikin manyan mutane a Sweden. Alamu kamar NT‑proBNP da sakamakon echo‑cardiography ma sun inganta. Sai dai gwajin ya ƙunshi mutane 443 ne kawai, daga yankin da ke da ƙarancin selenium, kuma ba a san wane sinadari ne ya haifar da sakamakon ba. Wannan shi ne abin da binciken KiSel‑10 ya bayyana, waɗanda za su iya amfana, da ƙuntatawar amincin da ya kamata a sani kafin a yi amfani da shi.

Approach: Macro science. Palette: D, bold color field.

An extreme close-up microscopy-style photograph of a single giant megakaryocyte cell, a large lumpy, lobed cell with a textured, slightly translucent surface, budding off dozens of tiny, smooth, disc-shaped platelets that drift away on fine stringy extensions. The cell and platelets are a warm pearly ivory with subtle coral-pink internal granules and a few small electric green (#00e676) fluorescent specks inside, suggesting recycling vesicles. The backdrop is a saturated, even tomato-red to deep orange color field with a soft gradient. Shot from slightly above at a three-quarter angle, with shallow depth of field so the nearest platelets are crisp and the distant ones melt into soft blur. Lighting is clean, diffuse and glowing from behind, giving gentle rim highlights. Mood: curious, precise, quietly cautionary. No text.
longevity

CoQ10 Ya Kwantar da ‘Tsoffin’ Platelet a Berayen Tsufa — Abin da Ya Kamata a Lura

BY NOVA CHEN ·

Sabuwar bincike a mujallar *Aging Cell* ya nuna CoQ10 na inganta aikin megakaryocytes masu tsufa a beraye, wanda ke rage haɗa‑haɗar platelet da ƙara kwanciyar su. Tasirin ya danganta da COPS3 da autophagy, amma binciken ya ƙunshi kawai beraye da ƙwayoyin a dakin gwaje‑gwaje; ba a sami bayanan mutane ba, kuma ba a tabbatar da cewa zai hana toshewar jini ba. Ga abin da ke nufi, abin da ba ya nufi, da kuma dalilin da ya sa masu amfani da magungunan rage jini su tattauna da likita kafin ɗaukar CoQ10.

This page is available in